Guided Therapeutics (GTHP) EBITDA Margin (2010 - 2025)
Guided Therapeutics (GTHP) reported EBITDA Margin of 120.34% for Q4 2025, up 5327966.0% on a YoY basis from N/an in Q4 2024, and up 85.11% sequentially from 808.33% in Q3 2025.
Guided Therapeutics (GTHP) EBITDA Margin (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of EBITDA Margin data on file, last reported at 120.34% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin rose 5327966.0% year-over-year to 120.34%; the trailing twelve-month figure through Dec 2025 stood at 309.26% (up 2981931.0% YoY), and the FY2025 full-year result was 309.26%, up 2980503.0% from the prior year.
- EBITDA Margin climbed to 120.34% in Q4 2025, from 808.33% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 120.34% in Q4 2025 to a low of 53400.0% in Q4 2024.
- A 5-year average of 11790.73% and a median of 3626.14% in 2023 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin plunged 5188438 bps in 2024 and surged 5327966 bps in 2025, its largest moves.
- Tracing GTHP's EBITDA Margin over 5 years: stood at 725.0% in 2021, then slumped by 5528 bps to 40800.0% in 2022, then surged by 96 bps to 1515.62% in 2023, then tumbled by 3423 bps to 53400.0% in 2024, then soared by 100 bps to 120.34% in 2025.
- Business Quant data shows GTHP's EBITDA Margin at 120.34% in Q4 2025, 808.33% in Q3 2025, and 652.14% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | -120.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -120.34% |
| Sep 30, 2025 | -808.33% |
| Jun 30, 2025 | -652.14% |
| Dec 31, 2024 | -53,400.00% |
| Mar 31, 2024 | -5,983.33% |
| Dec 31, 2023 | -1,515.63% |
| Jun 30, 2023 | -3,420.45% |
| Mar 31, 2023 | -3,831.82% |
| Sep 30, 2022 | -40,800.00% |
| Jun 30, 2022 | -14,340.00% |
| Mar 31, 2022 | -8,860.00% |
| Dec 31, 2021 | -725.00% |
| Sep 30, 2021 | -2,563.16% |
| Jun 30, 2021 | -28,050.00% |
| Dec 31, 2020 | -1,152.00% |
| Sep 30, 2020 | -198.70% |
| Dec 31, 2019 | -1,031.25% |
| Sep 30, 2019 | -18,800.00% |
| Jun 30, 2019 | -32,700.00% |
| Mar 31, 2019 | -1,427.78% |